Genomic alterations in the p53 tumour-suppressor gene 
The p53 tumour-suppressor gene encodes a 53 kDa nuclear phosphoprotein which is thought to protect cells against the accumulation of genetic alterations. Overexpression of the wild-type (wt) p53 protein and an increase in transcriptional transactivation activity, following treatment with DNAdamaging agents, lead to cell cycle arrest in the GI phase or the induction of apoptosis. (Vogelstein & Kinzler, 1992; Lane, 1993; Levine et al., 1994) . Abnormalities in the p53 gene are the most common genetic alteration in human cancer (Hollstein et al., 1991 ; Levine et al., 1991; Caron de Fromentel & Soussi, 1992) . In normal tissue wt p53 protein is difficult to detect, whereas in cells with p53 gene mutations, conformational changes and a prolonged biological half-life lead to accumulation of mutant p53 protein.
In human pancreatic cancer, genomic alterations in the p53 tumour-suppressor gene are frequently combined with mutations in the c-K-ras oncogene. Summarising the data from six groups (Barton et al., 1991; Ruggeri et al., 1992; Casey et al., 1993; Kalthoff et al., 1993; Scarpa et al., 1993; Perucho, personal communication) the mutation pattern of the p53 gene in pancreatic cancer shows a similar distribution to other gastrointestinal adenocarcinomas, with hotspots at positions 273, 248, 175 and additionally at positions 220 and 132.
Alterations of p53 cannot only be detected with molecular biological and immunohistochemical methods. In addition, mutant p53 proteins may serve as targets of the host immune system as tumour-specific antigens (Harris & Hollstein, 1993) . Several previous studies have described the detection of antibodies against p53 protein in the sera of patients with various malignant diseases (Crawford et al., 1982 (Crawford et al., , 1984 Caron de Fromentel et al., 1987; Davidoff et al., 1992; Hassapoglidou & Diamindis, 1992; Schlichtholz et al., 1992; Winter et al., 1992; Volkmann et al., 1993) .
The aim of this study was to investigate whether p53-specific antibodies could be found in the sera of patients with malignant and benign pancreatic diseases, since in previous analyses (Kalthoff et al., 1993) we were able to show specific p53 immunoreactivity in cytospin preparations derived from patients with pancreatic cancer and, in addition, in specimens from patients with acute and chronic pancreatitis.
The analysis of 160 sera was performed using two independently developed ELISA systems. To further substantiate the results, all sera were analysed by Western blot technique using a cell lysate of PancTu-l (Hamburg, Germany) and the analyses of the sera performed according to the manufacturer's recommendations. All sera were analysed in a second ELISA system kindly provided by T. Soussi, Paris (Schlichtholz et al., 1994) .
Cell line and culture conditions
The human pancreatic cell line PancTu-l (Dr M. v. Builow, Mainz, Germany) was routinely cultured in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 1 mM sodium pyruvate, 100 U ml1' penicillin and 100 U ml-' streptomycin (all from Life Technologies, Eggenstein, Germany (Figures I and 2) . At the time of serum sample collection this patient was suspected of having autoimmune hepatitis. One patient (serum no. 2,722) with acute pancreatitis, a prior history of pancreatitis and no signs of malignancy on ERCP or endoscopic ultrasonography, and who died from septic shock 1 month after admission to hospital, was positive in both ELISA systems (Table lb) . A reaction was seen with the Western blot technique using PancTu-I cell lysate as the antigen source and was confirmed by a strong signal in the Western blot with the recombinant wt p53 (Figures 1 and 2 Figures 1 and   2 ).
Discossdo
The results of the two independently developed ELISA systems for the detection of antibodies against p53 correlated well, both with each other and with the Western blot analysis using PancTu-l cell lysate and recombinant wt p53 as the antigen source.
Although the rate of p53 mutations in pancreatic tumours is of the order of that in other adenocarcinomas (>,50%), only a few cases of antibody response were found in this study. Antibodies against p53 were detected in 5/78 patients (6.4%) with pancreatic cancer. The detection rate for antibodies against p53 was reported to be 9-14% in breast cancer (Crawford et al., 1982; Caron de Freomentel et al., 1987; Davidoff et al., 1992; Schlichtholz et al., 1992) , 10% in lung cancer (Winter et al., 1992) , 12.5% in colorectal cancer (Crawford et al., 1984) , 20% in B-cell lymphoma (Caron de Fromentel et al., 1987) and 20% in hepatocellular carcinoma (Volkmann et al., 1993) .
In an analysis of 790 serum samples from patients with various malignancies, only 16 positive samples (2%) were identified by Hassapoglidou and Diamandis (1992) . The prevalence of p53 antibodies in the patients with pancreatic cancer in our study is lower than in serum samples of patients with colorectal cancer (Crawford et al., 1984) , despite the fact that the rate of p53 gene mutations in colorectal and pancreatic cancer is very similar, suggesting either a particular mutation pattern in pancreatic cancer with low immunogenicity or a generally suppressed immune system in these patients. Complexes between p53 protein and a 70kDa heat shock protein might be necessary for the antigenic presentation of p53 (Davidoff et al., 1992) . This putative prerequisite may only be fulfilled in a few pancreatic carcinomas.
In previous analyses (Kalthoff et al., 1993; Kessler et al., 1993) we were able to show specific p53 immunoreactivity in cytospin preparations derived from patients with pancreatic cancer (7/10) and, in addition, in specimens from patients with acute and chronic pancreatitis (9/13). The fact that antibodies against p53 were found in serum samples of patients with non-malignant pancreatic diseases may point to a p53 release and antigen processing with subsequent elicitation of a p53-directed antibody response by necroinflammatory benign diseases. Another hypothesis to explain the occurrence of p53 antibodies in these patients is the presence of as yet undetected malignancies. 
